Elon Musk: "This Is the Most Destructive Force in History"
Elon Musk claims a terrifying new economic force will put millions of Americans out of work. The ripple effects could nudge the US economy into a catastrophic tailspin. If this happens, you need to be prepared. That's why a former Trump advisor is sharing his contingency plan with the public. What is Musk talking about?
Donald Trump has sweeping plans for a second administration. Here's what he's proposed
WASHINGTON (AP) — Donald Trump has promised sweeping action in a second administration.
A promising schizophrenia drug showed mixed results. What does that mean for patients?
Some people who took a new schizophrenia drug for a year improved with only a few side effects, but many dropped out of the research, the company announced Thursday.
Crypto Profit Floodgates Open With Trump Presidency - Ad
As Bitcoin heads towards $100k, this video shows you how to make HUGE gains from Crypto's $82 Billion 'Trump-Pump'...Without buying a single Bitcoin! But you must get in before January 20th -- Trump's inauguration day -- for the biggest gains...
AstraZeneca Unveils Early Data From Chinese-Firm Partnered Oral Weight Loss Drug
AstraZeneca and Eccogene revealed promising trial data on ECC5004, an oral GLP-1 receptor agonist for obesity, showing safety, tolerability, and convenient dosing.
Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside
UCB and Biogen's Phase 3 lupus drug trial shows improved disease activity outcomes, with promising data leading to a second pivotal trial in 2024.
[Breaking] Classified Wargames Reveal Grave Threat From China - Ad
In multiple wargames, U.S. forces were overwhelmed and unable to stop Chinese amphibious assaults from seizing the island. With tensions at a boiling point, the economic fallout could be devastating. Get the details on the weapons makers set to boom if war breaks out.
Trump Picks Dr. Oz As Centers For Medicare And Medicaid Services Administrator
President-elect Donald Trump on Tuesday said that he will nominate celebrity physician Dr. Mehmet Oz to lead the Centers for Medicare & Medicaid Services (CMS).
GSK's Investigational Liver Disease Candidate Hits Primary Goal In Late-Stage Study To Treat Relentless Itch In Some Patients
GSK's phase 3 GLISTEN trial demonstrated linerixibat's potential to treat relentless itch in PBC patients, meeting its primary endpoint.
The Dark Truth About AI Stocks - Ad
All the signs show the AI market is about to reverse. And unless you know what's really going on in this sector, you could be wiped out. Inside this new expose, you'll discover exactly how the AI crisis will unfold... how you can prepare for it before it's too late... and how you can potentially profit from it, too.
Encouraging Early Data From Next-Gen Study Puts Bristol Myers' CAR T Therapy In The Spotlight For Autoimmune Diseases
Bristol Myers reports promising preliminary results for its next-gen CAR T therapy CC-97540, showing safety and early efficacy in a Phase 1 study for severe autoimmune diseases.
Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026
Biogen downgraded to Hold by Needham amid projected flat revenues until 2026. Leqembi and other new product sales show gradual growth amid market challenges.
There's Only ONE AI Company That Matters - Ad
It's not Nvidia, AMD, IBM, or any new startup. It's not even an artificial intelligence company... yet it holds the key to the entire AI market. Get all the details of the critical technology that the entire AI sector needs to survive.
Cannabis Could Save $29 Billion Per Year In U.S. Healthcare Costs, Says CEO
Leafwell CEO Emily Fisher reveals medical cannabis could save U.S. healthcare $29 billion annually, citing new research.
Stock Of The Day: Is Pfizer Set Up To Rally?
Shares of Pfizer (PFE) may be about to reverse and head higher. They are both oversold and at a support level.
The 7th Trillion Dollar Company? - Ad
There are six American companies worth over $1 trillion. Could there be a seventh soon? This company signed a massive deal with Apple until 2040 and is also involved with Nvidia, Google, and Samsung. Could this be the next trillion-dollar company? A top stock expertpicker thinks so.
A Croatian corruption investigation snares the health minister and several others
ZAGREB, Croatia (AP) — Croatia's health minister and several others were detained on Friday on suspicion of corruption as part of an investigation launched by the European prosecutor's office, authorities said.
European committee takes a second look at Alzheimer's drug and now says it should be approved
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after .
Former Trump Advisor Warning: "An Economic Rupture Is Coming" - Ad
The legendary financier Brad Thomas served on Trump's advisory board for years. Now he's stepping forward with a terrifying new warning. "Even the rich aren't safe," he says. "I'm taking steps to protect my family."
Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density
Amgen addresses safety concerns for its weight loss drug MariTide after new data suggests a potential 4% reduction in bone density at the highest dose.
Bird Flu Puts Teen In Critical Condition As Canada Reports First Human Case: What You Need To Know
Pfizer and Moderna are hustling to develop an mRNA bird flu vaccine, the same technology used in the companies' respective COVID-19 vaccines.
What Does Trump's Presidency Mean for Elon Musk's AI Venture? - Ad
As new allies, Trump and Musk could reshape America's AI future. Elon Musk's AI startup, xAI, might gain the edge it needs to dominate the industry. A shift in government support, fewer barriers, and a potential "backdoor" into the AI race are just the beginning. Is xAI set to become Elon's most powerful venture yet?
Justice Department sues to block UnitedHealth Group's $3.3 billion purchase of Amedisys
NEW YORK (AP) — The Justice Department is suing to block UnitedHealth Group's $3.3 billion purchase of Amedisys, citing concerns the combination would hinder access to home health and hospice services in the U.S.
Struggling Genetic Testing Company 23andMe To Lay Off 40% Of Its Workforce, Discontinues All Therapeutic Programs
23andMe restructures, cutting 40% of its workforce and ending its therapeutic programs to save $35 million annually while exploring strategic alternatives.
AI Market Shock Coming November 19th? - Ad
Jeff Brown predicts an AI market shift, potentially happening by November 19th, led by Bill Gates' Stargate project. Get ahead of the curve before the next AI market shock.
Donald Trump's Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare
Trump's second term could bring significant changes to U.S. healthcare, with cuts to ACA subsidies and potential Medicare privatization.
Moderna's Q3 Earnings Beat Overshadowed By Vaccine Demand Slowdown And Market Share Concerns, Analysts Warn
Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over upcoming COVID and RSV sales.
Shocking Footage from Bill Gates' $100 Billion AI Project - Ad
Jeff Brown flew to Wisconsin to witness Bill Gates' $100 billion AI project firsthand. What he uncovered will blow your mind!
HIV Drugmaker Gilead Reports Strongest Quarterly Performance Of 2024, Analysts Boost Price Target On Raised Outlook
Gilead stock surges after Q3 earnings beat estimates and raised FY 2024 guidance, with strong HIV drug sales and analyst upgrades boosting investor confidence.
CVS Health Q3 profit misses estimates, company names new leaders at 2 divisions
CVS Health fell short on third-quarter profit, but it posted strong sales and the health care giant shook up leadership under new CEO David Joyner that has sent shares plunging.
Bill Gates' Mysterious New AI Project Revealed - Ad
Tech expert Jeff Brown uncovers Bill Gates' latest AI project, Stargate, which Forbes claims could reshape everything we think we know about our world.
Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential
Piper Sandler initiates coverage of Nektar Therapeutics, citing REZPEG's Treg-focused action as a potential breakthrough for Alopecia areata treatment.
Why Is Integra LifeSciences Stock Soaring On Monday?
Integra LifeSciences' Q3 results show adjusted EPS of $0.41 and revenue at $380.83 million. Codman segment grows 1%, while Tissue Tech sees a 3.6% decline.
Wavebot: The Automated Trading Tool for This Bull Market - Ad
October through December are historically among the most bullish months for crypto. WaveBot -- an automated trading tool that takes all the guesswork out of profiting in crypto. It trades key levels, buying dips and selling at the perfect time, 24/7. All you need to do is set it up. After that, WaveBot takes care of everything.
Teladoc Health Q3 Earnings: Revenue Beat, EPS Beat, Shares Jump 10%
Teladoc Health shares are moving higher in extended trading Wednesday after the company reported financial results for the third quarter that topped analyst expectations.
Eli Lilly Q3 Earnings: Mounjaro Sales More Than Double, Takes $2.98 Billion Hit To Profit, Cuts Annual Outlook, Stock Tanks
Eli Lilly's stock falls as Q3 earnings miss estimates. 2024 guidance lowered due to IPR&D costs.
Apple's AI Dream Team: The Companies You Don't Know - Ad
Apple's debut AI device is set to redefine the market, but here's the twist -- they could be backed by a network of under-the-radar companies. These could be the real winners as Apple enters the AI race.
LENZ Therapeutics' Investigational Drug For Age-Related Blindness Aces Pivotal China Trial, Analyst Says Data Readout May Strengthen Position For Ex-U.S. Partnerships
LENZ Therapeutics and Corxel Pharmaceuticals announced Phase 3 data for LNZ100, showing significant presbyopia improvements, supporting potential FDA approval.
Stakes Are High For Nebraska's Medical Marijuana Families: Why They're Pushing For Cannabis Legalization
Nebraska families push for medical cannabis legalization, citing urgent need for treatment options for severe conditions as ballot nears.
Information, charts or examples are for illustration and educational purposes only and not for individualized investment management This message contains commercial elements, such as advertising. We only send these offers to those who have opted in to our newsletter. Past performance is not indicative of future results. For these reasons we strongly suggest trading in a DEMO/Simulated account. The information provided by us is for educational and informational purposes only. We make no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended and have not determined if the statements and opinions of the advertiser are accurate, correct or truthful. If you use, act upon or make decisions in reliance on information contained or any external source linked within it, you do so at your own peril and agree to hold us, our officers, directors, shareholders, affiliates and agents without fault.